Day: October 25, 2021

TAALERI PLC                STOCK EXCHANGE RELEASE                25 OCTOBER 2021 AT 9:45 (EEST) Taaleri Plc’s CEO changes – Peter Ramsay appointed as new CEO Taaleri Plc’s CEO Robin Lindahl resigns, and the company’s Board of Directors has appointed MSc (econ.) Peter Ramsay as the new CEO. Lindahl will immediately leave the company’s operational management. Peter Ramsay starts as CEO on 1 December 2021. He has been a member of Taaleri’s Board of Directors since March 2021, and will resign from this position immediately. Ramsay (born 1967) has most recently worked as the Chief Investment Officer and CFO of the family company Veikko Laine Oy since 2014. Prior to that, he served as Fim Oyj’s Group CEO and Chief Investment Officer. Ramsay has worked for a total of 30 years in various management and expert positions in the financial...

To the Nasdaq Copenhagen 25 October 2021 Debtor distribution data (CK92) Pursuant to s 24 Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes debtor distribution data for callable mortgage bond series as at 22 October 2021 in the attached file. Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/filarkiv/. For further information about data format and contents, please refer to the Nasdaq website. Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21. Yours sincerelyNykredit Realkredit A/SAttachmentsDebtor distribution data – Nykredit Realkredit A_S – 25-10-2021debisams – 25102021 ...

H1 2021 results H1 2021 gross margin: €40.3 million, up 18% at constant currency rates H1 2021 EBITDAr1: €9.4 million, 23% of gross margin H1 2021 adjusted2 net income: €8.9 million Q3 2021 gross margin: €20.3 million, up 32% on a pro forma basis Commercial and financial targets for 2021 reiterated:2021 gross margin guidance of around €85 million and EBITDAr target of between 22% and 25% Simplified mandatory takeover bid submitted by Ardian, the new majority shareholder of Artefact following the acquisition of a controlling interest Artefact’s Board of Directors issues a favorable opinion on Ardian’s draft offerParis, October 25, 2021 – 8.30 am CEST – Artefact (FR0000079683 – ALATF – eligible for PEA-PME equity savings plans), an expert in data transformation for major brands, is today reporting its 2021 interim results and its Q3...

Montrouge, on October 25, 2021CREDIT AGRICOLE S.A. ANNOUNCES THE REPAYMENT OF ITS Undated deeply subordinated notes issued on February 4, 2005 (ISIN: FR0010161026)* and Undated deeply subordinated notes issued on May 31, 2007 (ISIN: US225313AA37 – USF22797FJ25)* Crédit Agricole S.A. (the “Issuer”) today announces:The redemption (the “2005 Note Redemption”) of all of its undated deeply subordinated notes issued on February 4, 2005 (ISIN: FR0010161026) (the “2005 Notes”), on February 4, 2022 (the “2005 Note Redemption Date”).The 2005 Notes will be redeemed in accordance with Condition 6(2)(a) (General Call Option) of the Terms and Conditions of the 2005 Notes (the “2005 Note Terms and Conditions”) at a price equal to 100% of the principal amount plus the amount of any interest accrued up to and excluding the 2005 Note...

Press release Villejuif, on October 25, 2021 CREDIT LYONNAIS ANNOUNCES THE CONVENING OF A GENERAL MEETING OF THE HOLDERS OF ITS Undated participating notes issued on October 22, 1984 (ISIN: FR0000140071) Undated subordinated notes issued on November 4, 1985 (ISIN: FR0000584997) TO OBTAIN THEIR APPROVAL FOR THE INCLUSION OF AN EARLY REDEMPTION OPTION AT PAR, EXERCISABLE BY CREDIT LYONNAIS, IN THE TERMS AND CONDITIONS OF THE SECURITIES THEY HOLD AND ANNOUNCES THAT IT IS CONSIDERING THE POSSIBILITY OF THE REDEMPTION OF ITS Undated subordinated notes issued on January 5, 1987 (ISIN: FR0000165912) Crédit Lyonnais (the “Issuer”) today announces the convening of a general meeting of holders (each a “General Meeting of Holders”):of its undated participating notes (titres participatifs) issued on October 22, 1984, with an amount outstanding...

San Juan, Puerto Rico, Oct. 25, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – BOTS, Inc. (OTC: BTZI), (“BOTS” or “The Company”), a global technology conglomerate specialized in Blockchain-based solutions including decentralized finance applications, cybersecurity, crypto generation, mining, equipment repair, and warranties announced today that the Company invites all holders of $PRES – the world’s first commemorative presidential coin minted on a blockchain – to swap out their Omni protocol based $PRES for Binance Smart Chain based coins that allow holders to trade PRES on Pancakeswap, a popular decentralized exchange. Current owners of $PRES on the Omni and potential crypto traders may find information about President Trump (COIN: PRES) on the Binance Smart Chain Explorer here: https://bscscan.com/token/0x19b8213b09b76f4bf01464559f7b915669065f22#balances The...

Rapid Revenue Growth*Amounts shown are in CADAchieved a number of firsts and records including: Seventh consecutive quarter of double-digit revenue growth Seventh consecutive quarter of high digit accelerated profitable growth Record quarterly EBITDA Commenced trading on NASDAQ in September CEO purchased over CAD$3.7 million worth of shares on the open market NEW YORK and TORONTO and HERZLIYA, Israel, Oct. 25, 2021 (GLOBE NEWSWIRE) — InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(“InterCure” or the “Company”) today announced preliminary unaudited revenue of CAD$24 million (NIS 61 million) for the third quarter of 2021, representing another record quarter of high sequential and year-over-year revenue growth.  All amounts are expressed in Canadian dollars ($) or New Israeli Shekels...

ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer Management to host Conference Call on Monday, October 25,at 8:30am EDT/ 2:30pm CEST        The trial did not meet its primary endpoint of overall survival The prespecified subgroup of patients treated with eryaspase and an irinotecan-based chemotherapy demonstrated an interesting trend of survival benefit, which merits further investigation Patients treated with eryaspase demonstrated superior disease control compared to patients treated with chemotherapy only. Other secondary endpoints showed nominal improvement The safety profile of eryaspase was consistent with earlier clinical trials results and safety reviews ERYTECH will now focus on its late-stage program in hypersensitive ALL and confirms its intention to...

Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex diseaseDupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing positive results from first Phase 3 trial Dupixent is the first and only biologic to show positive, clinically meaningful Phase 3 results in these patients Data continue to support well-established safety profile of Dupixent Regulatory filings planned for 2022PARIS and TARRYTOWN, N.Y. – October 25, 2021 – Results from a second Phase 3 trial assessing the investigational use of Dupixent® (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE) demonstrated that the trial met its co-primary endpoints...